X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/15/2862719/18362/en/Amarin-to-Report-First-Quarter-2024-Financial-Results-and-Host-Conference-Call-on-May-1-2024.html
https://www.globenewswire.com/news-release/2024/04/08/2859112/18362/en/Amarin-Highlights-Key-Data-Providing-Mechanistic-Insights-into-Eicosapentaenoic-Acid-EPA-at-ACC-24.html
https://www.globenewswire.com/news-release/2024/04/06/2858811/18362/en/New-REDUCE-IT-Analyses-Show-VASCEPA-VAZKEPA-Icosapent-Ethyl-Benefit-in-High-Risk-Cardiovascular-Disease-Patient-Subgroups.html
https://www.globenewswire.com/news-release/2024/04/03/2856860/18362/en/Amarin-Provides-Update-on-VAZKEPA-Icosapent-Ethyl-Intellectual-Property-Portfolio-in-Europe.html
https://www.fiercepharma.com/pharma/teva-follows-suit-after-hikmas-2023-complaint-arguing-amarin-locked-drug-ingredient-supply
https://www.globenewswire.com//news-release/2024/02/15/2829894/18362/en/Amarin-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Host-Conference-on-February-29-2024.html
https://www.globenewswire.com//news-release/2024/01/22/2812941/18362/en/Amarin-Chairman-CEO-Issue-Letter-to-Shareholders.html
https://www.globenewswire.com//news-release/2024/01/10/2806970/18362/en/Amarin-Provides-Preliminary-Fourth-Quarter-2023-Selected-Financials-and-Outlines-Key-Priorities-For-2024.html
https://www.globenewswire.com//news-release/2023/12/11/2793825/18362/en/Amarin-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html
https://www.globenewswire.com//news-release/2023/11/12/2778635/18362/en/New-REDUCE-IT-Analyses-Show-VASCEPA-icosapent-ethyl-Associated-with-29-Percent-Relative-Risk-Reduction-Compared-with-Placebo-in-Prespecified-Subgroup-of-Patients-with-Metabolic-Syn.html
Market Place
Share 
